A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,500,000 shares of KPTI stock, worth $2.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,500,000
Previous 1,663,300 110.43%
Holding current value
$2.8 Million
Previous $1.43 Million 269.58%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.72 - $1.66 $1.32 Million - $3.05 Million
1,836,700 Added 110.43%
3,500,000 $5.29 Million
Q4 2023

Feb 14, 2024

BUY
$0.68 - $1.31 $1.13 Million - $2.18 Million
1,663,300 New
1,663,300 $1.43 Million
Q4 2022

Feb 14, 2023

BUY
$2.48 - $5.93 $1.91 Million - $4.57 Million
770,713 New
770,713 $2.62 Million
Q2 2021

Aug 16, 2021

SELL
$8.11 - $11.11 $10.9 Million - $15 Million
-1,349,800 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$9.85 - $17.69 $11 Million - $19.7 Million
-1,115,200 Reduced 45.24%
1,349,800 $14.2 Million
Q4 2020

Feb 16, 2021

SELL
$14.15 - $17.19 $10.6 Million - $12.9 Million
-747,931 Reduced 23.28%
2,465,000 $38.2 Million
Q3 2020

Nov 16, 2020

SELL
$14.14 - $19.71 $506,325 - $705,775
-35,808 Reduced 1.1%
3,212,931 $46.9 Million
Q2 2020

Aug 14, 2020

SELL
$16.6 - $25.25 $7.88 Million - $12 Million
-474,793 Reduced 12.75%
3,248,739 $61.5 Million
Q1 2020

May 15, 2020

SELL
$14.38 - $27.72 $912,669 - $1.76 Million
-63,468 Reduced 1.68%
3,723,532 $71.5 Million
Q4 2019

Feb 14, 2020

BUY
$9.23 - $19.67 $19.3 Million - $41.1 Million
2,087,000 Added 122.76%
3,787,000 $72.6 Million
Q3 2019

Nov 14, 2019

BUY
$5.66 - $11.85 $9.62 Million - $20.1 Million
1,700,000 New
1,700,000 $16.4 Million

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $63.8M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.